DK0880360T3 - Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop - Google Patents
Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitopInfo
- Publication number
- DK0880360T3 DK0880360T3 DK97903448T DK97903448T DK0880360T3 DK 0880360 T3 DK0880360 T3 DK 0880360T3 DK 97903448 T DK97903448 T DK 97903448T DK 97903448 T DK97903448 T DK 97903448T DK 0880360 T3 DK0880360 T3 DK 0880360T3
- Authority
- DK
- Denmark
- Prior art keywords
- epitope
- nucleic acid
- peptide containing
- vaccination
- vaccines
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9602777.6A GB9602777D0 (en) | 1996-02-12 | 1996-02-12 | Delivery vehicle |
US1650696P | 1996-04-30 | 1996-04-30 | |
GBGB9614548.7A GB9614548D0 (en) | 1996-07-11 | 1996-07-11 | A delivery vehicle |
US2411696P | 1996-08-16 | 1996-08-16 | |
PCT/GB1997/000396 WO1997028818A1 (en) | 1996-02-12 | 1997-02-12 | Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0880360T3 true DK0880360T3 (da) | 2003-01-27 |
Family
ID=27451395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97903448T DK0880360T3 (da) | 1996-02-12 | 1997-02-12 | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0880360B1 (da) |
JP (1) | JP2000505802A (da) |
AT (1) | ATE225668T1 (da) |
AU (1) | AU724716B2 (da) |
CA (1) | CA2244110A1 (da) |
DE (1) | DE69716240T2 (da) |
DK (1) | DK0880360T3 (da) |
ES (1) | ES2184990T3 (da) |
PT (1) | PT880360E (da) |
WO (1) | WO1997028818A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
ATE271876T1 (de) * | 1999-07-26 | 2004-08-15 | Ashok Rajgarhia | Verwendung einer synergistischen zusammensetzung zur herstellung eines medikaments zur behandlung von lebererkrankungen |
WO2003082327A2 (en) * | 2002-03-28 | 2003-10-09 | Brenntag Biosector A/S | Combined dna/protein vaccine compositions |
RU2311911C2 (ru) | 2002-07-05 | 2007-12-10 | Липоксен Текнолоджиз Лимитед | Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
EP2742951B1 (en) | 2004-09-14 | 2016-02-03 | Argos Therapeutics, Inc. | Strain independent amplification of HIV polynucleotides |
CA2601705A1 (en) * | 2005-04-01 | 2006-10-12 | Wyeth | Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
SI2569008T1 (sl) | 2010-05-14 | 2020-02-28 | Baxalta Incorporated | Himere OSPA in njihova uporaba v cepivih |
SI2590626T1 (sl) | 2010-07-06 | 2016-01-29 | Glaxosmithkline Biologicals S.A. | Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA |
EP3243526B1 (en) | 2010-07-06 | 2019-11-27 | GlaxoSmithKline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
US10487332B2 (en) | 2010-07-06 | 2019-11-26 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of RNA |
HRP20230185T8 (hr) | 2010-08-31 | 2023-07-21 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za isporuku rna koja kodira imunogen |
JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
US9023367B2 (en) | 2012-07-27 | 2015-05-05 | Baxter International Inc. | Compositions comprising chimeric OSPA molecules and methods of use thereof |
WO2023280807A1 (en) * | 2021-07-05 | 2023-01-12 | Evaxion Biotech A/S | Vaccines targeting neisseria gonorrhoeae |
WO2024038407A1 (en) * | 2022-08-19 | 2024-02-22 | Seqirus Inc. | Lipid nanoparticle comprising a dna-binding protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9305759D0 (en) * | 1993-03-19 | 1993-05-05 | Medical Research Council And T | Hiv therapy method and agents |
EP0714308A4 (en) * | 1993-08-26 | 1998-07-29 | Univ California | METHOD, COMPOSITIONS AND DEVICES FOR THE DELIVERY OF NAKED POLYNUCLEOTIDES THAT ENCODE BIOLOGICALLY ACTIVE PEPTIDES |
GB9319772D0 (en) * | 1993-09-24 | 1993-11-10 | Therexsys Ltd | Therapeutic agent |
WO1996041606A2 (en) * | 1995-06-08 | 1996-12-27 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
-
1997
- 1997-02-12 AU AU18005/97A patent/AU724716B2/en not_active Ceased
- 1997-02-12 ES ES97903448T patent/ES2184990T3/es not_active Expired - Lifetime
- 1997-02-12 CA CA002244110A patent/CA2244110A1/en not_active Abandoned
- 1997-02-12 JP JP9528316A patent/JP2000505802A/ja not_active Ceased
- 1997-02-12 DK DK97903448T patent/DK0880360T3/da active
- 1997-02-12 AT AT97903448T patent/ATE225668T1/de not_active IP Right Cessation
- 1997-02-12 EP EP97903448A patent/EP0880360B1/en not_active Expired - Lifetime
- 1997-02-12 WO PCT/GB1997/000396 patent/WO1997028818A1/en active IP Right Grant
- 1997-02-12 PT PT97903448T patent/PT880360E/pt unknown
- 1997-02-12 DE DE69716240T patent/DE69716240T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69716240T2 (de) | 2003-06-26 |
DE69716240D1 (de) | 2002-11-14 |
JP2000505802A (ja) | 2000-05-16 |
WO1997028818A1 (en) | 1997-08-14 |
AU724716B2 (en) | 2000-09-28 |
ATE225668T1 (de) | 2002-10-15 |
PT880360E (pt) | 2003-02-28 |
EP0880360A1 (en) | 1998-12-02 |
CA2244110A1 (en) | 1997-08-14 |
ES2184990T3 (es) | 2003-04-16 |
AU1800597A (en) | 1997-08-28 |
EP0880360B1 (en) | 2002-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0880360T3 (da) | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop | |
PL347977A1 (en) | Novel methods for therapeutic vaccination | |
Martin et al. | Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis | |
HK1048590A1 (en) | Compositions and methods for identifying antigens which alicit an immune response | |
DK0900380T3 (da) | Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper | |
Lawson et al. | Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: a model for the study of molecular mimicry in the pathogenesis of viral myocarditis. | |
ATE468127T1 (de) | Ii-key/antigene epitop-hybrid-peptid-vakzine | |
WO1995029193A3 (en) | Melanoma antigens | |
DK0677533T3 (da) | Antistoffer mod epitoper med homologi til selv-antigener, fremgangsmåder til fremstilling og anvendelser deraf | |
EP0794797A4 (en) | METHODS AND EQUIPMENT FOR IMMUNIZING A HOST BY ADMINISTERING NAKED POLYNUCLEOTIDES ENCODING ANTIGEN PEPTIDES | |
NO924780L (no) | Ekspresjon av spesifikke immunogener ved bruk av virusantigener | |
US20170043003A1 (en) | New m.tuberculosis vaccines | |
WO2000073430A3 (de) | Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind | |
DK0555276T3 (da) | Immunogene komplekser, især iscomer | |
EP0762891A1 (en) | Immunogenic pharmaceuticals | |
PT1119630E (pt) | Construcoes de acido nucleico para imunizacao genetica | |
NO954318L (no) | Immunogent preparat av OspC-antigenvaksiner for forhindring og behandling av Lymesykdom, samt rekombinante fremgangsmåter for fremstilling av slike antigener | |
EA012436B1 (ru) | Композиции для иммунизации против микобактерий | |
AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
Chowdhury et al. | Generation of high titer antisera in rabbits by DNA immunization | |
Decroix et al. | Mucosal Immunity Induced by Intramuscular Administration of Free Peptides In‐Line with PADRE: IgA Antibodies to the ELDKWA Epitope of HIV gp41 | |
MXPA03010527A (es) | Composicion de vacuna. | |
Gao et al. | A novel DNA vaccine containing multiple TB‐specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG | |
WO2002000250A3 (en) | Hiv-1 vaccines and screening methods therefor | |
EP1502602A3 (en) | Methods for therapeutic vaccination |